Lyell Immunopharma, Inc.
LYEL · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $40K | $60K | −33.3% |
| Operating income | −$269M | −$359M | +24.9% |
| Net income | −$274M | −$343M | +20.0% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 4, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $0K | $0K | |
| Operating income | −$48.3M | −$37.3M | −29.5% |
| Net income | −$45.5M | −$38.8M | −17.3% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Lyell Immunopharma's revenue in FY2025?
- $40K in FY2025 (Fiscal year ended Dec 31, 2025), −33.3% vs $60K a year earlier, per its 10-K filed Mar 2026.
- Was Lyell Immunopharma profitable in FY2025?
- No: net income was −$274M and operating income −$269M in FY2025.
- What was Lyell Immunopharma's revenue in Q3 2026?
- $0K (n/a vs a year earlier), per its Form 10-Q filed Nov 4, 2026.